VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs) Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6 ...
Preliminary phase 3 trial data indicate padeliporfin vascular targeted photodynamic therapy has favorable efficacy and acceptable safety for low-grade UTUC. The use of padeliporfin vascular targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results